- €134.62m
- €162.14m
- €52.95m
- 58
- 26
- 42
- 33
Annual balance sheet for Lavipharm SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1.93 | 1.64 | 18.2 | 8.44 | 5.59 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 13.1 | 15.4 | 17.1 | 21.7 | 18.3 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 23.3 | 26 | 45.6 | 45.7 | 45 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 16.4 | 16.7 | 17.1 | 19.5 | 21.4 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 50.5 | 52.7 | 114 | 115 | 125 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 18.8 | 23.2 | 45.7 | 35.8 | 39.1 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 62.2 | 62.7 | 73.9 | 72 | 72.5 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -11.7 | -9.98 | 40.3 | 42.7 | 53 |
| Total Liabilities & Shareholders' Equity | 50.5 | 52.7 | 114 | 115 | 125 |
| Total Common Shares Outstanding |